Acute Lymphocytic Leukemia All Pipeline Insight
DelveInsight’s, “Acute Lymphocytic Leukemia (ALL) – Pipeline Insight, 2023,” report provides comprehensive insights about 150+ companies and 160+ pipeline drugs in Acute Lymphocytic Leukemia (ALL) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Acute Lymphocytic Leukemia (ALL) Understanding
Acute Lymphocytic Leukemia (ALL): Overview
Acute Lymphocytic Leukemia (ALL) (ALL) is also called acute lymphoblastic leukemia. “Acute” means that the leukemia can progress quickly, and if not treated, would probably be fatal within a few months. ""Lymphocytic"" means it develops from early (immature) forms of lymphocytes, a type of white blood cell.
ALL starts in the bone marrow (the soft inner part of certain bones, where new blood cells are made). Most often, the leukemia cells invade the blood fairly quickly. They can also sometimes spread to other parts of the body, including the lymph nodes, liver, spleen, central nervous system (brain and spinal cord), and testicles (in males). Some cancers can also start in these organs and then spread to the bone marrow, but these cancers are not leukemia.
Symptoms
The early signs and symptoms of ALL may be like the flu or other common diseases. Some of the commeon sign and symtoms are:
- Weakness or feeling tired.
- Fever or drenching night sweats.
- Easy bruising or bleeding.
- Petechiae (flat, pinpoint spots under the skin, caused by bleeding).
- Shortness of breath.
- Weight loss or loss of appetite.
- Pain in the bones or stomach.
- Pain or feeling of fullness below the ribs.
- Painless lumps in the neck, underarm, stomach, or groin.
- Having many infections.
Diagnosis
The following tests and procedures may be used:
Physical exam and health history: An exam of the body to check general signs of health, including checking for signs of disease, such as infection or anything else that seems unusual. A history of the patient's health habits and past illnesses and treatments will also be taken.
Complete blood count (CBC) with differential: A procedure in which a sample of blood is drawn and checked for the following:
- The number of red blood cells and platelets.
- The number and type of white blood cells.
- The amount of hemoglobin (the protein that carries oxygen) in the red blood cells.
- The portion of the blood sample made up of red blood cells.
Bone marrow aspiration and biopsy: The removal of bone marrow, blood, and a small piece of bone by inserting a hollow needle into the hipbone or breastbone. A pathologist views the bone marrow, blood, and bone under a microscope to look for abnormal cells.
Treatment
Four types of standard treatment are used for Acute Lymphocytic Leukemia (ALL):
- Chemotherapy: It is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Radiation therapy: Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing
- Chemotherapy with stem cell transplant: Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell transplant is a treatment to replace the blood-forming cells
- Targeted therapy: Targeted therapy is a type of treatment that uses drugs or other substances to attack cancer cells. Targeted therapy may cause less harm to normal cells than chemotherapy or radiation therapy do.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Acute Lymphocytic Leukemia (ALL) R&D. The therapies under development are focused on novel approaches to treat/improve Acute Lymphocytic Leukemia (ALL).
- In July 2016, Jazz Pharmaceuticals and Pfenex announced an agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates.
- In June 2018, Cellectis stated that the US Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application to initiate a phase I clinical trial for UCART22
Acute Lymphocytic Leukemia (ALL) Emerging Drugs Chapters
This segment of the Acute Lymphocytic Leukemia (ALL) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute Lymphocytic Leukemia (ALL) Emerging Drugs
CPX-351: Jazz Pharmaceuticals
Vyxeos (cytarabine and daunorubicin) liposome for injection, or CPX-351, is an investigational product being evaluated for the treatment of AML and is a combination of cytarabine and daunorubicin encapsulated within a nano-scale liposome at a 5:1 molar ratio. It is currently in phase II stage of development for ALL.
JZP-458: Jazz Pharmaceuticals
JZP-458 is being developed by Jazz Pharmaceuticals for the treatment of Acute Lymphoblastic Leukemia. It is currently in phase II/III stage of development.
UCART22: Cellectis
UCART22 is one of Cellectis’ wholly owned, allogeneic, off-the-shelf gene-edited T-cell product candidates designed for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Like CD19, CD22 is a cell surface antigen expressed from the pre-B-cell stage of development through mature B-cells. CD22 expression occurs in more than 90% of patients with B-ALL. It is currently in phase I stage of development.
JZP-341: Jazz Pharmaceuticals
JZP-341 is being developed by Jazz Pharmaceuticals for the treatment of Acute Lymphoblastic Leukemia. It is currently in preclinical stage of development.
Further product details are provided in the report……..
Acute Lymphocytic Leukemia (ALL): Therapeutic Assessment
This segment of the report provides insights about the different Acute Lymphocytic Leukemia (ALL) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Acute Lymphocytic Leukemia (ALL)
There are approx. 150+ key companies which are developing the therapies for Acute Lymphocytic Leukemia (ALL). The companies which have their Acute Lymphocytic Leukemia (ALL) drug candidates in the most advanced stage, i.e. phase II/III include Jazz Pharmaceuticals and others
Phases
DelveInsight’s report covers around 160+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Acute Lymphocytic Leukemia (ALL) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravenous
- Oral
- Parenteral
- Subcutaneous.
- Molecule Type
Products have been categorized under various Molecule types such as
- Gene therapies
- Small molecule
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Acute Lymphocytic Leukemia (ALL): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Acute Lymphocytic Leukemia (ALL) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Lymphocytic Leukemia (ALL) drugs.
Acute Lymphocytic Leukemia (ALL) Report Insights
- Acute Lymphocytic Leukemia (ALL) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Acute Lymphocytic Leukemia (ALL) Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Acute Lymphocytic Leukemia (ALL) drugs?
- How many Acute Lymphocytic Leukemia (ALL) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Lymphocytic Leukemia (ALL)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Lymphocytic Leukemia (ALL) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Acute Lymphocytic Leukemia (ALL) and their status?
- What are the key designations that have been granted to the emerging drugs?
